BioCorRx Selects Covance For Non-Clinical Studies, Announces The Addition Of Dr. Bal S. Brar To Its Drug Development Team, Plans Pre-IND Meeting With FDA

ANAHEIM, CA, Nov. 28, 2016 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announces several operational developments as well as provides a strategic initiative update:
  • BioCorRx has announced that it has selected Covance, Inc. as the Contract Research Organization (CRO) for non-clinical studies of its new injectable naltrexone formulation, BICX101, being developed under its BioCorRx Pharmaceuticals subsidiary.
  • Covance, Inc. is scheduled to initiate first-study on December 22, 2016; and expects completion of first-study within 4-5 weeks from start date.
  • BioCorRx is planning the request for a pre-IND meeting with the FDA and anticipates a meeting date sometime in Q1 2017.
  • Dr. Balbir S. Brar has joined BioCorRx as a lead drug development study design consultant for the subsidiary.

BioCorRx Engages Covance, Inc. as its CRO:

Covance, Inc. is an international CRO with headquarters in Princeton, New Jersey, and provides drug development and testing services. The purpose of the studies with Covance is to help determine the optimal dose strength of BioCorRx's proprietary lead-candidate formulation. BioCorRx's once-a-month injectable naltrexone is being developed in partnership with TheraKine, Ltd. through an agreement announced earlier this year in which BioCorRx will retain worldwide rights to the new formulation for the treatment of addiction using TheraKine's underlying patented delivery technology.

Naltrexone is a non-addictive opioid antagonist that has already been approved by the FDA in other forms for the treatment of alcohol and opioid dependence. It can reduce or eliminate cravings for alcohol and opioids as well as block dangerous effects of opioid use such as overdose (commonly seen in heroin use). BioCorRx seeks to approve a more efficient delivery of naltrexone with the prospect of better patient adherence to monthly injections; as well as easier administration of the injection by healthcare providers.

If you liked this article you might like

Health Care Stocks Still Healthy Despite Higher Hedging Costs